HOFFMAN ESTATES, Ill. & KNOXVILLE, Tenn.--(BUSINESS WIRE)--April 8, 2005--Siemens Medical Solutions USA, Inc., a wholly owned subsidiary of Siemens AG (NYSE:SI), and CTI Molecular Imaging, Inc. (Nasdaq:CTMI) announced today that the antitrust waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to the previously announced tender offer to acquire all the issued and outstanding shares of CTI Molecular Imaging, Inc. has been terminated. The Federal Trade Commission (FTC) has informed Siemens that the request for early termination of the 15-calendar day waiting period prescribed by the HSR Act was granted. Siemens Medical Solutions, through its wholly owned subsidiary MI Merger Co., commenced on April 1, 2005, a tender offer for all of the outstanding shares of common stock of CTI Molecular Imaging, Inc. for $20.50 per share, net to the seller in cash.
The tender offer is being made pursuant to an Agreement and Plan of Merger, dated as of March 18, 2005 among Siemens Medical Solutions USA, Inc., MI Merger Co. and CTI Molecular Imaging, Inc. The tender offer remains open until 12:00 midnight New York City time, on Thursday, April 28, 2005, unless extended. Following completion of the tender offer, any remaining shares of CTI Molecular Imaging, Inc. will be acquired in a merger at the same price.
